This Psychedelics Stock Was Up More Than 20% Last Week, Outperforming Tesla, Nvidia and GameStop
Psychedelics have picked up more and more momentum on Wall Street, with famed investors such as Kevin O’Leary and Peter Thiel recognizing the potential in the psych drug industry.
Psychedelic drugs, such as psilocybin mushrooms and LSD, were once seen merely as a way for college students and concert goers to escape reality or at least enhance it. Now, these drugs are being heavily considered by doctors throughout the world as a way to treat various mental illnesses and other health problems.
Throughout the last five trading days, Atai Life Sciences (NASDAQ: ATAI), has skyrocketed, outperforming big names such as Tesla Inc (NASDAQ: TSLA), NVIDIA Corporation (NASDAQ: NVDA) and GameStop Corp (NYSE: GME).
Here’s how the returns break down throughout the last five trading days:
Atai - up more than 23% from last Wednesday’s open
GameStop- up more than 14%
Tesla- up more than 12%
NVIDIA- up more than 7%
What Does Atai Do?
Atai Life Sciences is a pre-clinical biotech company focused on treating
various mental illnesses and disorders using psychedelic drugs. The company has drugs in its pipeline to cure or alleviate the effects of treatment-resistant depression, schizophrenia and more.
Atai is using psilocybin, ketamine, MDMA and other similar drugs to attack these mental illnesses. Thiel, a major investor in Atai, has invested $12 million through his VC firm, Thiel Capital.
Photo Courtesy of Unsplash
See more from Benzinga
Kobe Bryant Bought 10% Of BodyArmor in 2014: Here's How Much That Investment Is Worth Now
Elon Musk's Net Worth Grew By The Value Of These 3 Companies Combined Today
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
